India Sprycel case set for January hearing; BDR to hold production
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's court case against the Indian firm BDR Pharmaceuticals concerning its anticancer Sprycel (dasatinib) will now be heard in January next year, with BDR, also a contender for a compulsory licence for the product, indicating that it will not manufacture the drug until then.